Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2017 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2022.
Oster C, Schmidt T, Agkatsev S, Lazaridis L, Kleinschnitz C, Sure U, Scheffler B, Kebir S, Glas M. Oster C, et al. Among authors: agkatsev s. Neurooncol Adv. 2023 Sep 4;5(1):vdad105. doi: 10.1093/noajnl/vdad105. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37811538 Free PMC article. Review.
Gender disparity regarding work-life balance satisfaction among German neuro-oncologists: a YoungNOA survey.
Kebir S, Lazaridis L, Wick W, Platten M, Tabatabai G, Combs SE, Schmidt T, Agkatsev S, Blau T, Mäurer I, Kahlert U, Sagerer A, Berberich A, Heider S, Müther M, Bodensohn R, Behling F. Kebir S, et al. Among authors: agkatsev s. Neuro Oncol. 2022 Sep 1;24(9):1609-1611. doi: 10.1093/neuonc/noac114. Neuro Oncol. 2022. PMID: 35639965 Free PMC article. No abstract available.
Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma.
Schmidt T, Agkatsev S, Feldheim J, Oster C, Blau T, Sure U, Keyvani K, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Scheffler B, Kebir S, Glas M, Lazaridis L. Schmidt T, et al. Among authors: agkatsev s. Neurooncol Adv. 2023 Jul 20;5(1):vdad090. doi: 10.1093/noajnl/vdad090. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37547266 Free PMC article.
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma.
Lazaridis L, Bumes E, Cäcilia Spille D, Schulz T, Heider S, Agkatsev S, Schmidt T, Blau T, Oster C, Feldheim J, Stummer W, Kessler AF, Seidel C, Grauer O, Hau P, Sure U, Keyvani K, Herrlinger U, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Breuer S, Hattingen E, Scheffler B, Kebir S, Glas M. Lazaridis L, et al. Among authors: agkatsev s. Neurooncol Adv. 2022 Aug 24;4(1):vdac137. doi: 10.1093/noajnl/vdac137. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36284931 Free PMC article.
A Genomic DNA Reporter Screen Identifies Squalene Synthase Inhibitors That Act Cooperatively with Statins to Upregulate the Low-Density Lipoprotein Receptor.
Kerr AG, Tam LCS, Hale AB, Cioroch M, Douglas G, Agkatsev S, Hibbitt O, Mason J, Holt-Martyn J, Bataille CJR, Wynne GM, Channon KM, Russell AJ, Wade-Martins R. Kerr AG, et al. Among authors: agkatsev s. J Pharmacol Exp Ther. 2017 Jun;361(3):417-428. doi: 10.1124/jpet.116.239574. Epub 2017 Mar 30. J Pharmacol Exp Ther. 2017. PMID: 28360334 Free PMC article.